Warning: Invalid argument supplied for foreach() in /home/clarifycpan/public_html/wp-content/themes/Skylit-Medical/header.php on line 127

[band bgcolor=”#e9e8e6″ bordertop=”1px solid #d1d0cf” borderbottom=”1px solid #d1d0cf”]
[motion type=”fade” direction=”bottom” offset=”200″]
[row]

[icon type=”book”] Board and Advisors

[/row]
[/motion]
[/band]

[band]

[row]

[columns]

[column width=”one-tenth”]
[motion type=”slide” direction=”right”]
[font size=”80px” lineheight=”120px” textalign=”center”][iconworks type=””” color=”#04a1dc”][/font]
[/motion]

[/column]

[motion type=”slide” direction=”right”]

[column width=”five-tenth”]

DAVID HALE[br]CHAIRMAN

[/column]

[/motion]
[/columns]

[columns]
[column width=”one-tenth”]
[/column]

[motion type=”slide” direction=”right”]

[column width=”five-tenth”]
David Hale is currently Chairman of Hale BioPharma Ventures, LLC, a private company involved in the development of biotechnology, specialty pharma, diagnostic and device companies. He was previously President and CEO of CancerVax Corporation, which merged with Micromet, Inc., where he served as Chairman until its acquisition by Amgen Inc. in 2012.

He is a serial entrepreneur who has been involved in the formation and development of a number of biomedical companies. In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, he served as COO, President and then Chief Executive Officer, when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc., and a co-founder and Chairman of Viagene, Inc. from 1987 to 1995.

Prior to joining Hybritech, Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc. Mr. Hale is Chairman of the Board of Santarus, Inc., and Conatus Pharmaceuticals Inc., which are two public biopharmaceutical companies.

He also serves as Chairman of Crisi Medical Systems, Inc., Ridge Diagnostics, Inc., Agility Clinical, Inc., Advantar Laboratories, Inc., Intrepid Therapeutics, Inc., Biocept, Inc., and Katama Pharmaceuticals. He served as Chairman of SkinMedica until its acquisition by Allergan in 2012. Mr. Hale also serves on the Board of Directors of BIOCOM, the San Diego EDC and he is a co-founder and a director of CONNECT. He also serves as Chairman of the Board of Trustees of Rady Children’s Hospital.

[/column]
[/motion]

[column width=”one-tenth”][/column]

[motion type=”slide” direction=”left”]

[column width=”three-tenth”]
David Hale

[/column]

[/motion]

[/columns]

[/row]

[/band]

[band]
[row]
[hr][hr][hr]
[/row]
[/band]

[band]

[row]

[columns]

[column width=”one-tenth”]
[motion type=”slide” direction=”right”]
[font size=”80px” lineheight=”120px” textalign=”center”][iconworks type=””” color=”#04a1dc”][/font]
[/motion]

[/column]

[motion type=”slide” direction=”right”]

[column width=”five-tenth”]

Jim Sweeney [br]CEO AND BOARD MEMBER

Jim began his entrepreneurial journey at Sharp Hospital where he worked full time delivering hospital supplies while still in high school. He then spent three years in the U.S. Army Medical Corps where he ran a remote medical dispensary serving 2,500 families in Germany . He received a degree in business from San Diego State University
He has founded twelve medical companies including Caremark, CAPS, Coram, Bridge Medical, CardioNet and co founded OwnedOutcomes. He also led a successful LBO of McGaw Labs which he took public and is now owned by B. Braun.
His financing history includes raising over $2 billion of venture and expansion capital for his ideas, leading to over $25 billion in exit value of companies he founded.

[/column]

[/motion]

[column width=”one-tenth”][/column]

[motion type=”slide” direction=”left”]

[column width=”three-tenth”]

Slide1

[/column]

[/motion]

[/columns]

[/row]

[/band]

[band]
[row]
[hr][hr][hr]
[/row]
[/band]

[band]

[row]

[columns]

[column width=”one-tenth”]
[motion type=”slide” direction=”right”]
[font size=”80px” lineheight=”120px” textalign=”center”][iconworks type=””” color=”#04a1dc”][/font]
[/motion]

[/column]

[motion type=”slide” direction=”right”]

[column width=”five-tenth”]

Martyn Gross [br] BOARD MEMBER, Founder and VP of Innovation

Martyn Gross founded Clarify Medical as a frustrated psoriasis patient. He received his MBA from Rady School of Management, University of California, San Diego. Prior to founding Clarify Medical, Gross spun out a corporate subsidiary for a marketplace website.

As founder of Clarify Medical, he was accepted into the inaugural class of the StartR Accelerator in La Jolla, California, and, upon completion, was accepted into EvoNexus, a Commnexus Incubator, in La Jolla. Gross is a member of the Founder.org Class of 2015 as well as the Texas Medical Center X Accelerator.

[/column]

[/motion]

[column width=”one-tenth”][/column]

[motion type=”slide” direction=”left”]

[column width=”three-tenth”]

Martyn-9894_linkedin-3

[/column]

[/motion]

[/columns]

[/row]

[/band]

[band]
[row]
[hr][hr][hr]
[/row]
[/band]

[band]

[row]

[columns]

[column width=”one-tenth”]
[motion type=”slide” direction=”right”]
[font size=”80px” lineheight=”120px” textalign=”center”][iconworks type=””” color=”#04a1dc”][/font]
[/motion]

[/column]

[motion type=”slide” direction=”right”]

[column width=”five-tenth”]

JOHN BUHLER[br]BOARD MEMBER

[/column]

[/motion]
[/columns]

[columns]
[column width=”one-tenth”]
[/column]

[motion type=”slide” direction=”right”]

[column width=”five-tenth”]
John has significant business leadership and medical technology expertise stemming from a 31-year career with Natus Medical Inc., SenoRx Inc., Ultrasonix, GE Healthcare and Diasonics-VingMed Ultrasound. John has a proven track record of building and leading successful business teams that consistently achieve strong financial performance, operational efficiency and customer loyalty.

John most recently served as President and CEO of RF Surgical, where, in 30 months, he grew revenue significantly and guided the company to a $235M acquisition by Medtronic. Previously John served as President and Chief Operating Officer of Natus Medical Incorporated, a publicly traded medical device manufacturer focused on Neurology and Newborn Care.

John helped Natus grow its revenue and infrastructure from $219M to $362M in his 2.5 years with the company. Prior to Natus, John was President & CEO of SenoRx, Inc. a publicly traded medical device manufacturer focused on the Breast Care market. John completed the sale of SenoRx, Inc. in July 2010 to C.R. Bard at a 41% premium over the stock price during the 90 days prior to the proposed transaction.

[/column]
[/motion]

[column width=”one-tenth”][/column]

[motion type=”slide” direction=”left”]

[column width=”three-tenth”]
John Buhler

[/column]

[/motion]

[/columns]

[/row]

[/band]

[band]
[row]
[hr][hr][hr]
[/row]
[/band]

[band]

[row]

[columns]

[column width=”one-tenth”]
[motion type=”slide” direction=”right”]
[font size=”80px” lineheight=”120px” textalign=”center”][iconworks type=””” color=”#04a1dc”][/font]
[/motion]

[/column]

[motion type=”slide” direction=”right”]

[column width=”five-tenth”]

Rex Bright[br]BOARD MEMBER

Rex Bright is a Co-Founder of SkinMedica. Rex served as the Chief Executive Officer of SkinMedica Inc. from October 2001 to 2008 and served as its President since October 2001. He served as the President of Allergan Skin Care, which he successfully built into a leading skin care company.

He spent several years as a start-up and turnaround executive in the health care sector, where he served as President and Chief Executive Officer of several companies including Arcturus Pharmaceutical Corporation and Epoulon, Inc., two dermatology companies. Rex served as the Head of J&J Ortho Dermatologic Division, which markets Retin-A and Renova.
[/column]

[/motion]

[column width=”one-tenth”][/column]

[motion type=”slide” direction=”left”]

[column width=”three-tenth”]

Rex

[/column]

[/motion]

[/columns]

[/row]

[/band]

[band]
[row]
[hr][hr][hr]
[/row]
[/band]

[band]

[row]

[columns]

[column width=”one-tenth”]
[motion type=”slide” direction=”right”]
[font size=”80px” lineheight=”120px” textalign=”center”][iconworks type=””” color=”#04a1dc”][/font]
[/motion]

[/column]

[motion type=”slide” direction=”right”]

[column width=”five-tenth”]

Dr. Richard Gallo[br]Clinical Advisor

Richard L. Gallo, MD, PhD, is Professor of Medicine and Pediatrics, and Interim Chair for the Department of Dermatology at the University of California, San Diego. His research focuses on the role of the innate immune system in skin health and disease, focusing on antimicrobial peptides and aspects of the basic functions of the skin immune system.

He has contributed several landmark observations to the field of Dermatology including the first description of an antimicrobial peptide in mammalian skin, the first demonstration that mammals depend on antimicrobial peptides for defense against infection, and the first association of human diseases (atopic eczema and Rosacea) with a defect in antimicrobial peptide production. His work has been seen in some of the most prestigious scientific and medical journals and is well supported by grants from the NIH, the Veterans Administration, and private foundations.
[/column]

[/motion]

[column width=”one-tenth”][/column]

[motion type=”slide” direction=”left”]

[column width=”three-tenth”]

Richard Gallo

[/column]

[/motion]

[/columns]

[/row]

[/band]

[band]
[row]
[hr][hr][hr]
[/row]
[/band]

[band]

[row]

[columns]

[column width=”one-tenth”]
[motion type=”slide” direction=”right”]
[font size=”80px” lineheight=”120px” textalign=”center”][iconworks type=””” color=”#04a1dc”][/font]
[/motion]

[/column]

[motion type=”slide” direction=”right”]

[column width=”five-tenth”]

Dr. Jeff Benabio[br]Clinical Advisor

Dr. Benabio is a dermatologist and Physician Director of Innovation and Transformation at Kaiser Permanente, San Diego. He leads several innovation and process improvement projects including enterprise social networking for physicians, Lean healthcare initiatives and technology-enhanced healthcare delivery pilots. He is the voice behind, The Digital Doctor, a blog dedicated to educating patients about health and wellness.

An expert in social media, Dr. Benabio frequently writes on social media and technology and gives talks to healthcare professionals on topics such as managing your online reputation and how physicians can use social media to engage patients. Dr. Benabio is an award-winning speaker, giving a dozen talks a year on teleheath, social media and networking for healthcare workers, and the changing doctor/patient relationship. He has presented provocative talks on Reinventing the Physician at TEDx Penn Quarter and TEDx San Diego. Frequently quoted both online and in print, Dr. Benabio was named “A Rock Star of Dermatology” by Glamour Magazine, and O The Oprah Magazine, named him “One of America’s Top Doctors.”
[/column]

[/motion]

[column width=”one-tenth”][/column]

[motion type=”slide” direction=”left”]

[column width=”three-tenth”]

Richard Gallo

[/column]

[/motion]

[/columns]

[/row]

[/band]


Warning: Invalid argument supplied for foreach() in /home/clarifycpan/public_html/wp-content/themes/Skylit-Medical/section-social.php on line 3

Warning: Invalid argument supplied for foreach() in /home/clarifycpan/public_html/wp-content/themes/Skylit-Medical/footer.php on line 12